Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-OX40 in Metastatic Melanoma
NCT01416844Phase 2Withdrawn
- Start
- Sep 2012
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of medi-6469 in melanoma. Planned start Sep 2012; status: withdrawn.
02
Drugs
medi-6469
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01416844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01416844.